Top Science Longreads of 2013
By Ed Yong,
National Geographic
| 12. 23. 2013
I’m really optimistic about the future for long, deep, rich science reporting. There are more places that are publishing it, more ways of finding it, and a seemingly huge cadre of people who are writing it well. So without further ado, here’s a list of my top pieces of the year. It has blossomed to 15 from last year’s 12 because I was gripped by indecision and they’re all so good. In no particular order:
1)
Bones of Contention,
by Paige Williams for the New Yorker. The curious case of USA v. One Tyrannosaurus Bataar Skeleton frames this exquisitely crafted tale about a Florida man’s trade in Mongolian dinosaurs, and the amazing world of fossils, auctions, and private collectors.
“He sold sloth claws, elephant jaws, wolf molars, dinosaur ribs—a wide range of anatomical fragments that went, mostly, for between ten and fifty dollars. Increasingly, Florida Fossils got into triple digits, especially when Prokopi started selling dinosaur parts. In the fall of 2011, he sold two Mongolian oviraptor nests for more than three hundred and fifty dollars each, a...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...
By Katherine Bourzac, Nature | 07.10.2024
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...